Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27512811 | 0.81 | ALDH1A1 (0.44) | ALDH1A1CYP1A2CYP2D6MEN1CYP2C19 | |
| SCHEMBL10446678 | 0.78 | ALDH1A1 (0.54) | HSD17B10ALDH1A1CYP1A2CYP2D6MEN1 | |
| SCHEMBL1126356 | 0.77 | HSD17B10 (0.51) | HSD17B10ALDH1A1CYP1A2CYP2D6MEN1 | |
| SCHEMBL19925275 | 0.77 | HSD17B10 (0.51) | HSD17B10ALDH1A1CYP1A2CYP2D6MEN1 | |
| Benzene SCHEMBL27902631 | 0.77 | LMNA (0.63) | HSD17B10ALDH1A1CYP1A2CYP2D6MEN1 | |
| SCHEMBL81625 | 0.77 | LMNA (0.63) | HSD17B10ALDH1A1CYP1A2CYP2D6MEN1 | |
| SCHEMBL6348986 | 0.77 | HSD17B10 (0.51) | HSD17B10ALDH1A1CYP1A2CYP2D6MEN1 | |
| SCHEMBL11450426 | 0.77 | HSD17B10 (0.51) | HSD17B10ALDH1A1CYP1A2CYP2D6MEN1 | |
| SCHEMBL3172460 | 0.77 | HSD17B10 (0.51) | HSD17B10ALDH1A1CYP1A2CYP2D6MEN1 | |
| SCHEMBL7936687 | 0.77 | HSP90AA1 (0.55) | HSD17B10ALDH1A1CYP1A2CYP2D6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3089980-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2018-01-31 | — | — | EP | claimed |
| US-9670208-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-06-06 | — | — | US | claimed |
| US-20160304519-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-10-20 | — | — | US | claimed |
| EP-1942888-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2008-07-16 | — | — | EP | claimed |
| US-20070135435-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-14 | — | — | US | claimed |
| WO-2007056078-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-18 | — | — | WO | claimed |
| EP-0621037-B1 | Pyrido-pyrimidinediones, process for their preparation and their use as pharmaceuticals | HOECHST AG (DE) | 1999-07-07 | — | — | EP | claimed |
| US-5556854-A | CARDIOVASCULAR DISORDERS AND/OR NEUROGENERATIVE DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-09-17 | — | — | US | claimed |
| EP-0373891-B1 | Anti-tumour agents | ICI PLC (GB) | 1994-11-02 | — | — | EP | claimed |
| EP-0621037-A1 | Pyrido-pyrimidinediones, process for their preparation and their use as pharmaceuticals | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-10-26 | — | — | EP | claimed |
| EP-0373891-A2 | Anti-tumour agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-20 | — | — | EP | claimed |
| EP-3089980-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9670208-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-06-06 | — | — | US | disclosed |
| EP-3089980-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20160304519-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-5556854-A | CARDIOVASCULAR DISORDERS AND/OR NEUROGENERATIVE DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-09-17 | — | — | US | disclosed |
| EP-0373891-B1 | Anti-tumour agents | ICI PLC (GB) | 1994-11-02 | — | — | EP | disclosed |
| EP-0621037-A1 | Pyrido-pyrimidinediones, process for their preparation and their use as pharmaceuticals | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-10-26 | — | — | EP | disclosed |
| US-5089499-A | Anticarcinogenic agents; thymidylate synthetase inhibitors; antiallergens; psoriasis | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-02-18 | — | — | US | disclosed |
| EP-0373891-A2 | Anti-tumour agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135435-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | HSD17B10 2654/4885ALDH1A1 2159/4885CYP1A2 4665/4885 |
| US-20160304519-A1 | SERINE/THREONINE KINASE INHIBITORS | TTBK1, MAP3K1, TNNI3K | HSD17B10 2032/4885ALDH1A1 3535/4885CYP1A2 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.